LiveDNA empowers researchers, scholars, editors, reviewers, publishers, and institutions with a trusted digital identity and comprehensive professional profile.
Masataka Kusunoki

Masataka Kusunoki

LiveDNA ID: 81.23223
19 Publications
0 Editorial Roles
0 Projects

Education

Academic Background
  • Ph.D. Aichi Medical University, Japan Clinical Immunology | Completed: 1989

Publications (19)

Selected Scholarly Contributions
Luseogliflozin, a sodium glucose co-transporter 2 inhibitor, alleviates hepatic impairment in Japanese patients with type 2 diabetes.
Kusunoki, M., Y. Natsume, D. Sato, H. Tsutsui and T. Miyata et al.,
Drug Res., | Journal Article
10.1055/s-0042-111515
Self Masataka Kusunoki
2016
PPARĪ³ activation alters fatty acid composition in adipose triglyceride, in addition to proliferation of small adipocytes, in insulin resistant high-fat fed rats.
Sato, D., K. Oda, M. Kusunoki, A. Nishina and K. Takahashi et al.,
Eur. J. Pharmacol., | Journal Article
10.1016/j.ejphar.2016.01.012
Self Masataka Kusunoki
2016
The beneficial effects of the DPP-4 inhibitor alogliptin on hemoglobin A1c and serum lipids in Japanese patients with type 2 diabetes.
Kusunoki, M., D. Sato, T. Nakamura, Y. Oshida and H. Tsutsui et al.,
Drug Res., | Journal Article
10.1055/s-0035-1547254
Self Masataka Kusunoki
2016
Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato, D., M. Kusunoki, G. Shinzawa, Z. Feng, A. Nishina and T. Nakamura,
Autonomic Neurosci.: Basic Clin., | Journal Article
10.1016/j.autneu.2015.08.005
Self Masataka Kusunoki
2015
DPP-4 inhibitor teneligliptin improves insulin resistance and serum lipid profile in Japanese patients with type 2 diabetes.
Kusunoki, M., D. Sato, T. Nakamura, Y. Oshida and H. Tsutsui et al.,
Drug Res., | Journal Article
10.1055/s-0034-1390419
Self Masataka Kusunoki
2015
Black soybean extract improves lipid profiles in fenofibrate-treated type 2 diabetics with postprandial hyperlipidemia.
Kusunoki, M., D. Sato, K. Tsutsumi, H. Tsutsui, T. Nakamura and Y. Oshida,
J. Med. Food, | Journal Article
10.1089/jmf.2014.3234
Self Masataka Kusunoki
2015
Clinical effect of addition of beraprost sodium to pioglitazone treatment on the blood glucose levels in patients with type 2 diabetes mellitus.
Chen, T., M. Kusunoki, D. Sato, H. Tsutsui, T. Nakamura, T. Miyata and Y. Oshida,
Exp. Clin. Endocrinol. Diabetes, | Journal Article
10.1055/s-0033-1354356
Self Masataka Kusunoki
2013
Site dependency of fatty acid composition in adipose triacylglycerol in rats and its absence as a result of high-fat feeding.
Sato, D., T. Nakamura, K. Tsutsumi, G. Shinzawa and T. Karimata et al.,
Metab.: Clin. Exp., | Journal Article
10.1016/j.metabol.2011.05.012
Self Masataka Kusunoki
2012
Pioglitazone-induced body weight gain is prevented by combined administration with the lipoprotein lipase activator NO-1886.
Kusunoki, M., K. Tsutsumi, D. Sato, A. Nakamura and S. Habu et al.,
Eur. J. Pharmacol., | Journal Article
10.1016/j.ejphar.2011.07.030
Self Masataka Kusunoki
2011
Activation of lipoprotein lipase increases serum high density lipoprotein 2 cholesterol and enlarges high density lipoprotein 2 particles in rats.
Kusunoki, M., K. Tsutsumi, D. Sato, A. Nakamura and S. Habu et al.,
Eur. J. Pharmacol., | Journal Article
10.1016/j.ejphar.2011.06.040
Self Masataka Kusunoki
2011
NO-1886 (ibrolipim), a lipoprotein lipase activator, increases the expression of uncoupling protein 3 in skeletal muscle and suppresses fat accumulation in high-fat diet-induced obesity in rats.
Kusunoki, M., K. Tsutsumi, K. Iwata, W. Yin and T. Nakamura et al.,
Metab.: Clin. Exp., | Journal Article
10.1016/j.metabol.2005.06.005
Self Masataka Kusunoki
2005
Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.
Kusunoki, M., K. Tsutsumi, Y. Inoue, T. Hara and T. Miyata et al.,
Metab.: Clin. Exp., | Journal Article
10.1016/j.metabol.2003.08.016
Self Masataka Kusunoki
2004
Ethyl icosapentate (omega-3 fatty acid) causes accumulation of lipids in skeletal muscle but suppresses insulin resistance in OLETF rats.
Kusunoki, M., K. Tsutsumi, T. Hara, H. Ogawa and T. Nakamura et al.,
Metabolism, | Journal Article
10.1053/meta.2003.50012
Self Masataka Kusunoki
2003
A lipoprotein lipase activator, NO-1886 prevents impaired endothelium-dependent relaxation of aorta caused by exercise in aged rats.
Kusunoki, M., K. Tsutsumi, T. Hara, H. Ogawa and T. Nakamura et al.,
Exp. Gerontol., | Journal Article
10.1016/S0531-5565(02)00023-2
Self Masataka Kusunoki
2002
Correlation between lipid and glycogen contents in liver and insulin resistance in high-fat [ndash] fed rats treated with the lipoprotein lipase activator NO-1886.
Kusunoki, M., K. Tsutsumi, T. Hara, H. Ogawa and T. Nakamura et al.,
Metab.: Clin. Exp., | Journal Article
10.1053/meta.2002.32732
Self Masataka Kusunoki
2002
The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet.
Kusunoki, M., T. Hara, K. Tsutsumi, T. Nakamura and T. Miyata et al.,
Diabetologia, | Journal Article
10.1007/s001250051464
Self Masataka Kusunoki
2000
Amelioration of high-fat feeding-induced insulin resistance in skeletal muscle with the antiglucocorticoid RU486.
Kusunoki, M., G.J. Cooney, T. Hara and L.H. Storlien,
Diabetes, | Journal Article
10.2337/diab.44.6.718
Self Masataka Kusunoki
1995
Muscle glucose uptake during and after exercise is normal in insulin-resistant rats.
Kusunoki, M., L.H. Storlien, J. MacDessi, N.D. Oakes, C. Kennedy, D.J. Chisholm and E.W. Kraegen,
Am. J. Physiol.-Endocrinol. Metab., | Journal Article
10.1152/ajpendo.1993.264.2.E167
Self Masataka Kusunoki
1993
Influence of sympatho-adrenal system on insulin sensitivity using the euglycemic clamp technique.
Kusunoki, M., Y. Oshida, A. Iguchi, T. Iida and T. Suga et al.,
Diabetes Res. Clin. Pract., | Journal Article
10.1016/0168-8227(92)90157-M
Self Masataka Kusunoki
1992